Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides.

Abstract

Imiquimod is a topical immune response modifier that binds to Toll-like receptors 7 and 8 and induces alpha-interferon. We locally applied imiquimod 5% cream (Aldara) daily for 2 weeks on a PUVA- and retinoid-resistant plaque on the face of a patient with mycosis fungoides. The diagnosis was based on clinical appearance, histology and molecular studies. Most of the disease manifestations showed a clear remission during PUVA therapy combined with low-dose retinoids. However, the plaque on the face was PUVA resistant. Local imiquimod treatment resulted in the complete clearance of the plaque. The patient has now been in complete remission for 12 months.

• Authors: Reinhard Dummer, Mirjana Urosevic, Werner Kempf, Dmitry Kazakov, Günter Burg
• Journal: Dermatology (Basel, Switzerland) (Dermatology) Vol. 207 Issue 1 Pg. 116-8 ( 2003) ISSN: 1018-8665 [Print] Switzerland
• PMID: 12835571 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright 2003 S. Karger AG, Basel

Chemical References

• Adjuvants, Immunologic
• Aminoquinolines
• Imiquimod

Topics

• Adjuvants, Immunologic (administration & dosage)
• Administration, Topical
• Aged
• Aminoquinolines (administration & dosage)
• Follow-Up Studies
• Humans
• Imiquimod
• Male
• Mycosis Fungoides (diagnosis, drug therapy)
• PUVA Therapy
• Risk Assessment
• Skin Neoplasms (diagnosis, drug therapy)
• Treatment Outcome